Irtemazole 12.5 to 50 mg in 6 healthy, normouricaemic subjects caused a maximal decrease in plasma uric acid (after 8 to 12 h) of 46.5%. The uricosuric effect began during the first 60 min after drug administration and it lasted for 7 to 24 h. Renal uric acid excretion returned to its base line value after 8 to 16 h and uric acid clearance after 10.0 to 12.0 h. Doses of irtemazole between 12.5 and 37.5 mg produced a dose-related rise in the uricosuric effect. There was no essential difference between the uricosuric effect of 37.5 mg and 50 mg irtemazole. The D50 dose (that producing a half-maximal effect) was between 16.3 mg and 34.2 mg, (average 24.7 mg). The value of irtemazole in the management of hyperuricaemia and gout remains to be determined.

01 Oct 1989·Klinische Wochenschrift

Rapid onset of uricosuria after oral administration of irtemazole, an uricosuric substance

Article

Author: U Gresser ; N Zöllner ; U Kronawitter ; O Adjan

A single 50 mg dose of irtemazole was given orally to ten healthy male volunteers. The onset of effects was tested. Plasma uric acid began to decrease 15 to 25 min after irtemazole was administrated. Renal uric acid excretion and uric acid clearance increased 10 to 20 min after drug administration. Maximal renal uric acid excretion (mean 197.4 mg/h) and maximal uric acid clearance (mean 78.4 ml/min) were reached after 15 to 55 min. No side effects were observed. The effects of irtemazole occur earlier than those of benzbromarone. The therapeutic effects of long-term therapy remain to be investigated.

01 Oct 1989·Klinische Wochenschrift

Uricosuric effect of irtemazole in healthy subjects

Article

Author: N. Zöllner ; U. Gresser

Following a single dose of 50 mg irtemazole per os, plasma uric acid levels decreased after 1 h and fell to 53.5% of the original value within 6-12 h. Renal uric acid excretion increased up to 66 mg/h 30 min after drug application and reached its maximum of 151 mg/h 30 min later. Uric acid clearance also increased after 30 min and reached its maximum of 56 ml/min after 60 min. The response of the kidney to irtemazole is faster than to benzbromarone or probenecid. Lowering of plasma uric acid has a shorter-lasting effect than benzbromarone or probenecid. At 24 h after the application of 50 mg irtemazole the decrease of the plasma uric acid was between 15.4% and 30.0%, or 24.7% on average. Three days after the application the basic plasma uric acid levels were reached again.

100 Deals associated with Irtemazole

External Link

KEGG	Wiki	ATC	Drug Bank
D04617	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gout	Phase 2	BE	Janssen LP	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis